 | | Vol. 13.34 – 9 September, 2021 |
| |
|
|
| Investigators presented a single-cell and spatially resolved transcriptomics analysis of human breast cancers. They developed a single-cell method of intrinsic subtype classification to reveal recurrent neoplastic cell heterogeneity.
[Nature Genetics] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that patients with breast cancer did not accumulate sufficient intratumoral paclitaxel to induce mitotic arrest in tumor cells. Instead, clinically relevant concentrations induced multipolar mitotic spindle formation.
[Science Translational Medicine] |
|
|
|
| Mouse mammary tumor organoids were established by encapsulating tumor pieces in non-adhesive alginate and were treated with doxorubicin and latrunculin A to evaluate their application as a drug screening platform.
[Advanced Science] |
|
|
|
| The authors described identification of 1089 gene-centric common insertion sites (gCIS) from transposon-based screens in eight mouse models of breast cancer (BC). Most gCIS showed single allele disruption and many mapped to genomic regions showing high-frequency hemizygous loss in human BC.
[Nature Communications] |
|
|
|
| Scientists evaluated DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in clinically-annotated breast cancer tissue microarrays and correlated results with immune biomarkers. They found that high expression of DNA-PKcs was significantly associated with stromal and CD8+ tumor-infiltrating lymphocytes.
[npj Breast Cancer] |
|
|
|
| In estrogen receptor positive (ER+) cells, oncostatin M (OSM) robustly stimulated phosphorylation of known gp130 signaling targets STAT3, ERK and AKT, while CNTF activated STAT3 signaling. In ER– breast cancer cells, OSM alone stimulated AKT and ERK signaling.
[Journal of Bone and Mineral Research] |
|
|
|
| By knocking down the expression of TAZ in TNBC cells, researchers found that TAZ was essential for the maintenance of telomeres in TNBC cells and that loss of TAZ caused senescence phenotype of TNBC cells.
[Breast Cancer Research] |
|
|
|
| To identify novel small molecules that inhibit microtubule organization, investigators conducted sequential phenotypic screening of fission yeast and human cells and showed that one of the compounds, L1, bound to the colchicine-binding site of microtubules and exhibited a preferential potency against a panel of human breast cancer cell lines compared with a control non-cancer cell line.
[Open Biology] |
|
|
|
| To elucidate the underlying mechanisms that drive breast cancer stem cells (BCSCs) tumorigenicity in TNBC, scientists identified the long noncoding RNA BMP/OP-Responsive Gene (BORG) as an enhancer of BCSC phenotypes.
[Molecular Cancer Research] |
|
|
|
| The authors utilized TNBC as a model to discern mechanisms of resistance as it has been previously shown to be highly responsive to CDK7 inhibitors. After generating cell lines with acquired resistance, high throughput RNA-sequencing revealed significant upregulation of genes associated with efflux pumps and transforming growth factor-beta (TGF-β) signaling pathways.
[Journal of Biological Chemistry] |
|
|
|
| Researchers showed that RKIP inhibited cancer cell invasion and metastasis by stimulating RhoA anti-tumorigenic functions. Mechanistically, RKIP activated RhoA in an Erk2 and GEF-H1 dependent manner to enhance E-cadherin membrane localization and inhibit CCL5 expression.
[Scientific Reports] |
|
|
|
| Scientists investigated LGR5 expression in normal, benign, and malignant lesions of the human breast using RNA in situ hybridization, and suggested that LGR5 marked facultative stem cells that were involved in post injury regeneration instead of homeostatic stem cells.
[Scientific Reports] |
|
|
|
| Arthrifuranone A was isolation from an EtOAc-extract of Arthrinium pseudosinense culture medium and evaluated for its estrogenic activity using the MCF-7 estrogen responsive human breast cancer cells.
[Journal of Antibiotics] |
|
|
|
|
| An intense quest is ongoing for complementary tumor- or host-related predictive biomarkers in breast immuno-oncology. Among the upcoming biomarkers, quantity, immunophenotype and spatial distribution of tumor-infiltrating lymphocytes and other tumor microenvironment cells as well as immune gene signatures emerge as most promising and are being increasingly tested in clinical trials.
[ESMO Open] |
|
|
|
| Resveratrol (RES), a naturally occurring phytoalexin, has demonstrated anti-cancer activity in several disease models. The authors describe the STAT3 cascade signaling pathway and address the therapeutic targeting of STAT3 by RES as a tool to mitigate breast cancer.
[Cancer Cell International] |
|
|
|
|
| Bolt Biotherapeutics, Inc. announced that it has entered into a clinical collaboration and supply agreement with Bristol Myers Squibb to investigate Bolt Biotherapeutics’ BDC-1001 in combination with Bristol Myers Squibb’s PD-1 checkpoint inhibitor Opdivo®.
[Bolt Biotherapeutics, Inc.] |
|
|
|
|
| October 19 – 20, 2021
Virtual |
|
|
|
|
|
| | University of Glasgow – Glasgow, Scotland, United Kingdom |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | University of Pennsylvania – Philadelphia, Pennsylvania, United States |
|
|
|
| | The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
